Healing intestinal disease with oxygen

Clinically validated efficacy.
Novel oral administration.

Addressing an urgent public health threat

We are focused on the prevention of antibiotic-induced C. difficile colitis infections, a leading cause of healthcare-associated infections.

  • No vaccine hesitancy

  • No stewardship restrictions

Targeted prevention without systemic disruption

The LPOXY team is driven to protect people from this deadly antibiotic-induced superinfection.

  • - The Centers for Disease Control and Prevention considers C. difficile colitis an URGENT public health threat.

  • - C. difficile colitis afflicts nearly a half million Americans each year.

  • - 30,000 will die.

  • - There are no therapies or vaccines to prevent this antibiotic-induced superinfection.

LPOXY Therapeutics is developing a pill that taken with antibiotics gently increases the colon’s oxygen tension to prevent antibiotic-induced C. difficile colitis via multiple mechanisms.

Watch a video about antibiotics and C. difficile colitis here.

SIDIPREV™ orally-administered, metered-dose intestinal oxygen delivery is being developed for multiple indications

  • Antibiotic-induced C. difficile colitis superinfection prevention

    Oxygen’s clinical effectiveness established in humans

  • Inflammatory Bowel Diseases: Crohn's & Ulcerative Colitis

    Oxygen’s clinical effectiveness established in humans

  • Multiple Sclerosis

    Via oxygen’s effectiveness vs epsilon-toxin-producing C. perfringens

Latest Developments

For more information about our use and development of enteric aerobization therapy, contact us.